Safety and Efficacy of Glibenclamide Combined With Rt-PA in Acute Cerebral Embolism

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 306 participants.

Also called NCT03284463

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 306 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03284463
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03284463. Randomized; quadruple masking; primary purpose treatment. Start 2018-01-01 (actual); primary completion 2022-08-28 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Glibenclamide Combined With Rt-PA in Acute Cerebral Embolism
Acronym
SE-GRACE
Condition
Acute Stroke
Intervention (Drug)
Glibenclamide
Intervention (Drug)
Placebo
Lead sponsor
Nanfang Hospital, Southern Medical University (class: other)

Record details

Record id
cardio:ct-nct03284463
Content hash
25e49a3b814301e9c297314b3c3b2dbc81949ee1aa1d8103319ea70b16d3da47